Mannatech Appoints New CFO Yasir Haider
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Executive Appointment: Mannatech has appointed Yasir Haider as Chief Financial Officer, effective June 3, 2026, marking a significant shift in the company's financial leadership aimed at enhancing financial management efficiency.
- Interim Management: Haider was named Interim CFO on March 20, 2026, demonstrating the company's flexibility and adaptability during the search for a long-term financial leader, ensuring continuity in financial operations.
- Successor Transition: Haider succeeds former CFO James Clavijo, who contributed to the implementation of the company's financial strategy during his tenure, and this leadership change may impact the company's financial direction and strategy.
- Extensive Experience: Prior to joining Mannatech, Haider held senior finance leadership positions, including CFO and financial controller roles, providing a solid foundation for his new role and aiding in driving the company's financial health and growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTEX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTEX
About MTEX
Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mannatech Appoints New CFO Yasir Haider
- Executive Appointment: Mannatech has appointed Yasir Haider as Chief Financial Officer, effective June 3, 2026, marking a significant shift in the company's financial leadership aimed at enhancing financial management efficiency.
- Interim Management: Haider was named Interim CFO on March 20, 2026, demonstrating the company's flexibility and adaptability during the search for a long-term financial leader, ensuring continuity in financial operations.
- Successor Transition: Haider succeeds former CFO James Clavijo, who contributed to the implementation of the company's financial strategy during his tenure, and this leadership change may impact the company's financial direction and strategy.
- Extensive Experience: Prior to joining Mannatech, Haider held senior finance leadership positions, including CFO and financial controller roles, providing a solid foundation for his new role and aiding in driving the company's financial health and growth.
See More
Mannatech Q1 Financial Highlights
- Earnings Per Share: Mannatech reported a GAAP EPS of $0.49 for Q1, indicating stable profitability; however, the lack of growth compared to the previous year highlights the pressure the company faces in maintaining earnings.
- Revenue Decline: The company’s revenue of $24.92 million reflects a 6.2% year-over-year decrease, signaling weak market demand and intensified competition, which could impact future market share and growth potential.
- Financial Transparency: Mannatech has provided detailed financial information to enhance investor confidence, aiming to attract more attention despite current underperformance through transparent reporting.
- Market Challenges: With declining revenue and profitability pressures, Mannatech may need to reassess its market strategy to address competition and changing consumer demands in the industry.
See More
Mannatech Reports Q4 Financial Results with Significant Losses
- Financial Loss: Mannatech reported a Q4 GAAP EPS of -$5.94, indicating significant challenges in profitability and reflecting ongoing financial pressure on the company.
- Revenue Decline: The company's Q4 revenue of $26.6 million represents an 8.3% year-over-year decrease, suggesting weakened market demand that could impact future business growth and investor confidence.
- Deteriorating Cash Position: As of December 31, 2025, Mannatech's cash and cash equivalents fell to $6.2 million from $11.4 million as of December 31, 2024, highlighting increased liquidity risks that may limit operational flexibility.
- Uncertain Future Outlook: Given the poor financial performance, Mannatech faces pressure to reassess its business strategy, and investors should monitor how the company addresses current financial challenges to restore growth.
See More
Mannatech Reports $15.2 Million Net Loss for 2025 Fiscal Year
- Sales Decline: Mannatech reported fourth-quarter net sales of $26.6 million for 2025, an 8.2% decrease compared to the previous year, primarily due to the implementation of a new ordering system in North America that weakened sales momentum, indicating significant market pressure.
- Gross Margin Erosion: The gross margin for 2025 fell to 74.9% from 77.6% in 2024, largely driven by supply chain challenges and rising product costs, highlighting the company's difficulties in maintaining cost control amid increasing expenses.
- Increased Operating Loss: The company experienced an operating loss of $0.4 million in 2025, a stark contrast to the $1.4 million operating income in 2024, underscoring the challenges in operational efficiency in a deteriorating revenue environment.
- Tightening Cash Flow: As of December 31, 2025, Mannatech's cash and cash equivalents decreased to $6.2 million from $11.4 million in 2024, indicating heightened liquidity risks and the need for improved financial management to navigate future uncertainties.
See More
MANNATECH ANNOUNCES FINANCIAL RESULTS FOR Q4 AND FULL YEAR 2025
Financial Results Overview: The financial results for the fourth quarter and year-end of 2025 have been reported, highlighting key performance metrics and overall financial health.
Revenue and Profit Trends: The report indicates trends in revenue and profit, showcasing growth or decline compared to previous periods.
Operational Highlights: Key operational achievements and challenges faced during the year are summarized, providing insight into the company's performance.
Future Outlook: The report concludes with a forward-looking statement, outlining expectations and strategic plans for the upcoming year.
See More
Mannatech Files for Extension on Annual Report Submission
- Annual Report Delay: Mannatech has filed a Form 12b-25 with the SEC to delay the submission of its 2025 fiscal year annual report, originally due on March 31, 2026, now extended by 15 days to April 15, 2026.
- Compliance Measures: By submitting Form 12b-25, Mannatech ensures adherence to SEC regulations, although this delay may impact investor confidence, the company is committed to filing the report promptly to maintain transparency.
- Market Impact: This delay could negatively affect Mannatech's stock price, particularly as investor scrutiny on the company's financial health intensifies, potentially lowering market expectations for future growth.
- Business Outlook: Operating in over 25 markets globally, Mannatech faces challenges from COVID-19 and increased competition, yet remains focused on driving growth through science-backed nutritional products, with upcoming financial reports serving as critical indicators of strategic execution.
See More
Mannatech Appoints New CFO Yasir Haider
- Executive Appointment: Mannatech has appointed Yasir Haider as Chief Financial Officer, effective June 3, 2026, marking a significant shift in the company's financial leadership aimed at enhancing financial management efficiency.
- Interim Management: Haider was named Interim CFO on March 20, 2026, demonstrating the company's flexibility and adaptability during the search for a long-term financial leader, ensuring continuity in financial operations.
- Successor Transition: Haider succeeds former CFO James Clavijo, who contributed to the implementation of the company's financial strategy during his tenure, and this leadership change may impact the company's financial direction and strategy.
- Extensive Experience: Prior to joining Mannatech, Haider held senior finance leadership positions, including CFO and financial controller roles, providing a solid foundation for his new role and aiding in driving the company's financial health and growth.
See More
Mannatech Q1 Financial Highlights
- Earnings Per Share: Mannatech reported a GAAP EPS of $0.49 for Q1, indicating stable profitability; however, the lack of growth compared to the previous year highlights the pressure the company faces in maintaining earnings.
- Revenue Decline: The company’s revenue of $24.92 million reflects a 6.2% year-over-year decrease, signaling weak market demand and intensified competition, which could impact future market share and growth potential.
- Financial Transparency: Mannatech has provided detailed financial information to enhance investor confidence, aiming to attract more attention despite current underperformance through transparent reporting.
- Market Challenges: With declining revenue and profitability pressures, Mannatech may need to reassess its market strategy to address competition and changing consumer demands in the industry.
See More
Mannatech Reports Q4 Financial Results with Significant Losses
- Financial Loss: Mannatech reported a Q4 GAAP EPS of -$5.94, indicating significant challenges in profitability and reflecting ongoing financial pressure on the company.
- Revenue Decline: The company's Q4 revenue of $26.6 million represents an 8.3% year-over-year decrease, suggesting weakened market demand that could impact future business growth and investor confidence.
- Deteriorating Cash Position: As of December 31, 2025, Mannatech's cash and cash equivalents fell to $6.2 million from $11.4 million as of December 31, 2024, highlighting increased liquidity risks that may limit operational flexibility.
- Uncertain Future Outlook: Given the poor financial performance, Mannatech faces pressure to reassess its business strategy, and investors should monitor how the company addresses current financial challenges to restore growth.
See More
Mannatech Reports $15.2 Million Net Loss for 2025 Fiscal Year
- Sales Decline: Mannatech reported fourth-quarter net sales of $26.6 million for 2025, an 8.2% decrease compared to the previous year, primarily due to the implementation of a new ordering system in North America that weakened sales momentum, indicating significant market pressure.
- Gross Margin Erosion: The gross margin for 2025 fell to 74.9% from 77.6% in 2024, largely driven by supply chain challenges and rising product costs, highlighting the company's difficulties in maintaining cost control amid increasing expenses.
- Increased Operating Loss: The company experienced an operating loss of $0.4 million in 2025, a stark contrast to the $1.4 million operating income in 2024, underscoring the challenges in operational efficiency in a deteriorating revenue environment.
- Tightening Cash Flow: As of December 31, 2025, Mannatech's cash and cash equivalents decreased to $6.2 million from $11.4 million in 2024, indicating heightened liquidity risks and the need for improved financial management to navigate future uncertainties.
See More
MANNATECH ANNOUNCES FINANCIAL RESULTS FOR Q4 AND FULL YEAR 2025
Financial Results Overview: The financial results for the fourth quarter and year-end of 2025 have been reported, highlighting key performance metrics and overall financial health.
Revenue and Profit Trends: The report indicates trends in revenue and profit, showcasing growth or decline compared to previous periods.
Operational Highlights: Key operational achievements and challenges faced during the year are summarized, providing insight into the company's performance.
Future Outlook: The report concludes with a forward-looking statement, outlining expectations and strategic plans for the upcoming year.
See More
Mannatech Files for Extension on Annual Report Submission
- Annual Report Delay: Mannatech has filed a Form 12b-25 with the SEC to delay the submission of its 2025 fiscal year annual report, originally due on March 31, 2026, now extended by 15 days to April 15, 2026.
- Compliance Measures: By submitting Form 12b-25, Mannatech ensures adherence to SEC regulations, although this delay may impact investor confidence, the company is committed to filing the report promptly to maintain transparency.
- Market Impact: This delay could negatively affect Mannatech's stock price, particularly as investor scrutiny on the company's financial health intensifies, potentially lowering market expectations for future growth.
- Business Outlook: Operating in over 25 markets globally, Mannatech faces challenges from COVID-19 and increased competition, yet remains focused on driving growth through science-backed nutritional products, with upcoming financial reports serving as critical indicators of strategic execution.
See More
